Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity

Three companies that have outperformed the S&P 500 in 2025 announced meaningful buybacks alongside strong operational results: Keysight (KEYS, +23% YTD) beat sales and adjusted EPS with revenue up 10% and guided for ~19% sales growth next quarter, and expanded its repurchase program by $1.5 billion (bringing repurchase capacity to ~$110M + the new authorization, equal to ~4.7% of market cap). SEA (SE, ~+31% YTD) reported Shopee sales of $4.3 billion (+35%) and Garena revenue +31% but missed adjusted EPS, then authorized a $1 billion buyback (~1.2% of >$80B market cap) as management signals confidence after a sizable share price pullback. Solventum (SOLV, +29% YTD) delivered a Q3 beat, raised guidance, announced its first-ever $1 billion repurchase (~6.7% of market cap) after divesting a water-filtration unit to cut $2.7 billion of debt, retains $1.6 billion cash and plans up to $900 million for the Acera Surgical acquisition.

Analysis

Market structure: KEYS (buyback ~4.7% of market cap) and SOLV (~6.7%) are direct beneficiaries of EPS accretion and signaling; KEYS also remaps competitive dynamics in AI networking test equipment and indirectly boosts AVGO’s addressable market by accelerating advanced chip validation demand. SEA’s $1B authorization (~1.2%) is symbolic—it shores up equity but is unlikely to change sector pricing; it does, however, reduce float slightly and signals management sees value after a ~29% drawdown from the highs.

Risk assessment: Tail risks include regulatory action in Southeast Asia/Brazil against SEA (probability medium, impact high), execution/integration failure for SOLV’s Acera deal (low‑probability medium impact), and cyclical AI capex downturn hitting KEYS (medium). Immediate (days) effects: headline-driven volatility around earnings and deal announcements; short-term (weeks–months): EPS accretion realization and credit metric moves; long-term (quarters–years): structural demand for AI test equipment and SOLV’s leverage profile determine total returns.

Trade implications: Prefer asymmetric, event-driven allocations: tactical long KEYS (1.5–2.5% portfolio) into any <8% pullback or on next-quarter guide confirmation, using a 6–12 month call spread to cap cost; consider long SOLV (1–2%) ahead of Acera close with a 9–12 month time horizon but hedge with a 5–7% trailing stop given re-leverage risk. For SEA, only establish a small, conditional position (≤1% size) on >10% further weakness or after two consecutive quarters of margin expansion; pair idea: long SE vs short MELI (0.8:0.6 weighting) if you view SE’s SEA/Brazil recovery outsized vs LatAm competition.

Contrarian angles: The market is underestimating that SEA’s buyback is likely token—not transformative—so current enthusiasm may be overdone unless buyback pace accelerates beyond 1.2% cap. SOLV’s large first buyback plus a $900M acquisition could re-lever the balance sheet and negate the de‑risk from the water‑business sale; historical parallels show first buybacks after restructurings often precede renewed M&A rather than sustainable capital returns. Watch liquidity/float compression (>=5% reduction) as a short‑term squeeze risk and don’t conflate buyback authorization with immediate buyback execution.

Key Decisions for Investors

• Establish a 1.5–2.5% long position in KEYS (NYSE: KEYS) on a pullback of up to 8% or on confirmation of next-quarter guidance; implement a 6–12 month call‑spread (buy 12–15% OTM, sell 25–30% OTM) to cap premium outlay and target a 20–40% return if AI infrastructure demand persists.
• Accumulate a tactical 1–2% long in Solventum (NYSE: SOLV) with a 9–12 month horizon ahead of the Acera Surgical acquisition close; size exposure conservatively and set a 5–7% trailing stop because the $900M deal could re-lever the company and widen credit spreads.
• Take a conditional 0.8–1.0% long position in SEA (NYSE: SE) only after either (a) an additional >10% price decline from current levels or (b) two consecutive quarters of margin improvement; pair as long SE / short MELI (0.6% position) if conviction is regional-share recovery in Brazil versus LatAm competition.
• Avoid levering exposure to buyback beneficiaries indiscriminately; monitor corporate filings for actual repurchase execution (not just authorization) over the next 90 days and reduce positions by 50% if repurchase execution <25% of authorized amount within 6 months or if net leverage increases by >20% post-acquisition.